LM-2417 / Sino Biopharm - LARVOL DELTA

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=320 | Recruiting | Sponsor: LaNova Medicines Limited | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2027 ➔ Dec 2028

Enrollment open • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-2417 “NaPi2b/4-1BB BISPECIFIC ANTIBODY” IN CHINA (HKEXnews) - "This clinical study is an open-label, dose escalation and dose expansion Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LM-2417 for injection as a monotherapy or in combination with other anti-tumor drugs in patients suffering advanced malignant solid tumors."

Enrollment status • Solid Tumor

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=320 | Not yet recruiting | Sponsor: LaNova Medicines Limited | Initiation date: Dec 2024 ➔ Jun 2025

Trial initiation date • Oncology • Solid Tumor